Ipamorelin and sermorelin are almost never a real either-or. They bind different receptors, so a GHRH analog plus a secretagogue produced a GH response well above the sum of each alone in humans. The usual answer is both, with the GHRH analog as the base.
Ipamorelin and sermorelin are often framed as competitors. They are not. They act on different receptors, come from different drug classes, and do their best work together rather than in place of each other. The real question is not which one wins. It is why a considered protocol usually contains both, and which one belongs at the base of it.
- Sermorelin is a GHRH analog; ipamorelin is a secretagogue acting on the ghrelin receptor. Different receptors, different classes [1]
- Both end in a pulse of the body's own GH, which is why combining them is additive rather than redundant [2]
- Sermorelin clears in about 4 minutes and mirrors the natural nightly GH pulse [4]
- Ipamorelin's selectivity is real but shown in swine and rats, not humans [1]
- Ipamorelin's only published human efficacy trial missed its endpoint [3]
- Sermorelin held FDA approval as Geref until 2009; both are now dispensed compounded
The Core Difference Is the Receptor
Sermorelin is a GHRH analog. It is the first 29 amino acids of growth hormone-releasing hormone, and it works by binding the GHRH receptor on the pituitary to trigger a GH pulse. Ipamorelin reaches the same pituitary through a different door. It is a selective secretagogue that binds the ghrelin receptor, the receptor the hunger hormone ghrelin uses [1].
Both routes end in the same place: a pulse of the body's own growth hormone, released on the pituitary's own schedule. Neither delivers GH directly. That shared endpoint from two separate receptors is the entire reason the two get combined instead of chosen between.
| Sermorelin | Ipamorelin | |
|---|---|---|
| Drug class | GHRH analog | GH secretagogue |
| Receptor | GHRH receptor | Ghrelin receptor [1] |
| Half-life | About 4 minutes [4] | Short-acting, clears quickly |
| Dosing pattern | Nightly, mirrors natural pulse [4] | Short pulse, usually stacked |
| Human efficacy trials | Pediatric GHD, small adult studies | One published, endpoint missed [3] |
| FDA status | Approved as Geref, withdrawn 2009, now compounded | No approved product; compounding voted down 0 to 12 [6] |
| WADA status | Prohibited at all times [7] | Prohibited at all times [7] |
The Evidence Base for Each
Sermorelin has the longer clinical track record. It was used for years as a diagnostic and therapeutic GHRH analog, including in pediatric growth hormone deficiency, before its branded form was withdrawn. Its pharmacology and its nightly-pulse pattern are well described.
Ipamorelin's record is thinner and points somewhere unexpected. Its development never targeted body composition or aging. The only published human efficacy trial tested it for postoperative ileus, the slowdown of bowel function after surgery, and found a median time to first tolerated meal of 25.3 hours versus 32.6 hours on placebo, which did not reach statistical significance [3]. Development stopped afterward. The muscle and recovery uses it is now sold for were never the uses it was tested for.
What Ipamorelin's Selectivity Actually Means
Ipamorelin was introduced as the first selective growth hormone secretagogue, and selectivity is why it displaced older peptides like GHRP-6 and GHRP-2 [1]. In the foundational study, it raised GH without raising cortisol or ACTH even at doses more than 200 times its GH threshold, while the older secretagogues raised both [1].
The selectivity was measured in swine and rats, not people. The cortisol advantage is strongly suggested by animal data rather than proven in humans. It is a real point in ipamorelin's favor, stated more confidently on sales pages than the evidence supports [1].
Why They Are Stacked, Not Chosen Between
The strongest evidence in this whole comparison is the case for using both. A GHRH analog and a secretagogue act on separate receptors that converge on the same pituitary cells, so pushing both produces more GH than pushing either alone.
In healthy people, GH area under the curve was 686 for GHRH alone, 1787 for a secretagogue alone, and 4111 for the two together, well above the arithmetic sum [2]. That study paired GHRH with GHRP-6 rather than sermorelin with ipamorelin, so the exact magnitude is an extrapolation. The principle that the two classes are additive holds in humans.
This is why the sermorelin-plus-ipamorelin blend exists and why ipamorelin rarely appears as a solo protocol. Sermorelin supplies the GHRH-side pulse that mirrors natural release. Ipamorelin adds a second, ghrelin-side pulse on top of it. One is the base. The other is the addition.
Regulatory Standing
This is where the two diverge most, and it is rarely disclosed at point of sale. Sermorelin held FDA approval as Geref until the applications were withdrawn in 2009, and FDA determined the withdrawal was not for reasons of safety or effectiveness. It is now dispensed as a compounded preparation.
Ipamorelin has never had an approved product in any form. FDA lists ipamorelin acetate among bulk substances flagged as a compounding safety risk, citing immunogenicity concerns and serious adverse events including death when it was given intravenously for gastric motility [5]. In October 2024, an FDA advisory committee voted 0 in favor and 12 against permitting it for compounding [6].
Both are named on the 2026 WADA Prohibited List under section S2.2.4, prohibited at all times in and out of competition [7]. Neither is an option for anyone subject to anti-doping testing.
The Honest Verdict
There is no winner here, because the two are not solving the same problem. Forced to choose one to start with, the answer is the GHRH analog. Sermorelin has the longer track record, the nightly pattern that mirrors natural GH release, and the cleaner regulatory standing of the two [4]. Ipamorelin is the addition a prescriber layers on when a single pathway is not enough.
The disciplined path is the same one that applies to any GH-axis therapy. Start from a baseline IGF-1. Establish that a GHRH analog alone moves that number into range over 90 days. Add ipamorelin only under a prescriber working from your labs, not by default. A program that skips the baseline draw is the red flag, whether the vial holds one peptide or two.
The honest first move in this comparison is a GHRH analog built on a starting IGF-1, with ipamorelin added only if the labs call for it. SystemLabs tests IGF-1 before prescribing and formulates sermorelin, CJC-1295, and ipamorelin on clinical indication, so the second peptide is a decision rather than a default.
Frequently Asked Questions
What is the difference between ipamorelin and sermorelin?
They act on different receptors. Sermorelin is a GHRH analog that binds the GHRH receptor, while ipamorelin is a secretagogue that binds the ghrelin receptor [1]. Both trigger a pulse of the body's own GH, which is why they are usually combined rather than chosen between: a GHRH analog plus a secretagogue produced a GH response well above the sum of each alone in humans [2].
Is ipamorelin or sermorelin better?
Neither is better on its own terms, because they do different jobs. If you have to pick one to start with, the GHRH analog is the more sensible base: sermorelin has the longer clinical record, a nightly pattern that mirrors natural GH release, and the cleaner regulatory standing [4]. Ipamorelin is typically added to a GHRH analog rather than used alone.
Can you take ipamorelin and sermorelin together?
Yes, and that is the usual way both are used. They act on separate receptors, so combining them is additive rather than redundant, and the sermorelin-plus-ipamorelin blend is built on exactly that logic [2]. The combination should still come from a prescriber working from a baseline IGF-1, since no published trial has tested this specific pairing.
Does ipamorelin raise cortisol like older peptides?
The selectivity data says it does not, but that data is from swine and rats, not humans. In the foundational study, ipamorelin did not raise cortisol or ACTH above GHRH-stimulation levels even at more than 200 times its GH threshold, while GHRP-6 and GHRP-2 did [1]. Treat the cortisol advantage as strongly suggested by animal data rather than proven in people.
Are ipamorelin and sermorelin FDA approved?
Neither is FDA-approved today, and their histories differ. Sermorelin held approval as Geref until it was withdrawn in 2009 for reasons unrelated to safety or effectiveness, and is now compounded. Ipamorelin has never had an approved product; an FDA advisory committee voted 0 in favor and 12 against permitting it for compounding in October 2024 [6].
Why is ipamorelin rarely used by itself?
Because alone it is a single-pathway stimulus, and the evidence that makes it attractive is the supra-additive GH response when a GHRH analog and a secretagogue are combined [2]. Its own solo record is thin: the one published human efficacy trial, for postoperative ileus, missed its endpoint [3]. On a considered protocol it is the addition to a GHRH analog, not the base.
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6 Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 8045963. https://pubmed.ncbi.nlm.nih.gov/8045963/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men Journal of Clinical Endocrinology & Metabolism, 1994. PMID: 7962295. https://pubmed.ncbi.nlm.nih.gov/7962295/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
